13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • C-POST

    Acronym: 

    C-POST

    ACTRN/NCT /ethics: 

    NCT03969004

    Scientific title: 

    Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

    Summary of trial and patient characteristics

    Cancer Type Melanoma & other skin
    Trial Type Treatment
    Phase Phase III Tumour Stream Cutaneous Squamous Cell Carcinoma
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date 2019-06-04
    Molecular Target Anticipated End Date 2026-11-02
    Cancer Type Melanoma & other skin
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Cutaneous Squamous Cell Carcinoma
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2019-06-04
    Anticipated End Date 2026-11-02

    Trial Summary

    A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA

    Lay Summary

    Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

    Sponsor / Cooperative group

    Regeneron Pharmaceuticals

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Sue Yeend syeend@adelaidecancercentre.com.au 08 8292 2240 Dr Brian Stein Recruiting